New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
12:31 EDTGIS, ULTA, CTB, CELG, GMCR, ARO, SBUXOn The Fly: Midday Wrap
Stocks on Wall Street traded in a narrow band on either side of the flat-line in the early going, as the news flow continues to be dominated by developments between Russia and Ukraine. Stocks opened in quiet fashion and moved to the upside early in the session. The market was unable to hold its gains, however, and reversed course following a report that indicated that consumer sentiment has fallen this month. The averages crossed back into positive territory right before noon, but the market has remained in a narrow range throughout the morning's swings. ECONOMIC EVENTS: In the U.S., producer prices fell 0.1% overall in February, versus an expected increase of 0.2%. The core reading, which excludes food and energy, fell 0.2%, versus an expected increase of 0.1%. The Reuters/University of Michigan Consumer Sentiment Survey for March unexpectedly dropped to a four-month low of 79.9. The preliminary reading for the month was expected by analysts to have come in at 81.8, which would have been a slight bump from the prior 81.6 figure. In Europe, one person reportedly died and several were injured after violent clashes in the Ukrainian city of Donetsk amid demonstrations from those opposed to Russia’s military intervention in Crimea. Also, reports indicated the Russian military conducted another military exercise near Ukraine on Thursday. COMPANY NEWS: Shares of single-serve coffee machine maker Keurig Green Mountain (GMCR) rose nearly 9% after the company agreed to new terms in its deal with coffee giant Starbucks (SBUX). Research firm Buckingham said its views Keurig's amended deal with Starbucks as a positive event for both companies. The new agreement lets Keurig pursue additional premium unlicensed brands and provides Starbucks an opportunity for better margins, said the firm... Shares of teen retailer Aeropostale (ARO) fell almost 14% after its fourth quarter results and first quarter outlook missed analysts' consensus expectations. The retailer also entered a financing deal with private equity firm Sycamore Partners for a strategic partnership and $150M in senior secured credit facilities. Aeropostale will also issue convertible preferred stock to Sycamore that gives the firm the right to acquire up to 5% of the company's common stock at an exercise price of $7.25, the closing price of the company's common stock on March 12. MAJOR MOVERS: Among the notable gainers was beauty retailer Ulta Salon (ULTA), which advanced over 7% after the company’s fourth quarter results beat estimates. Also higher following its quarterly earnings report was tire maker Cooper Tire & Rubber (CTB), which rose nearly 8%. Among the noteworthy losers was Celgene (CELG), which dropped almost 3% after the U.K.'s healthcare guidance body issued new draft guidance on the use of the company's Revlimid drug. Also lower were shares of cereal and packaged foods maker General Mills (GIS), which slid 2% after the company warned its third quarter earnings could miss expectations. INDEXES: Near midday, the Dow was up 1.15, or 0.01%, to 16,110.04, the Nasdaq was up 1.74, or 0.04%, to 4,262.16, and the S&P 500 was virtually unchanged at 1,846.36.
News For GMCR;SBUX;ARO;ULTA;CELG;CTB;GIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 23, 2015
09:37 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
05:55 EDTCELGStocks with implied volatility movement; AMZN CELG
Subscribe for More Information
March 20, 2015
16:33 EDTSBUXStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
13:04 EDTCELGCelgene reports results from long-term efficacy,safety analyses of Otezla trials
Celgene announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla were presented at the 73rd Annual Meeting of the American Academy of Dermatology. OTEZLA is the company’s oral, selective inhibitor of phosphodiesterase 4 approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adults with active psoriatic arthritis. In ESTEEM 1 and 2, patients were randomized to treatment with OTEZLA 30 mg twice daily or placebo for the first 16 weeks. At week 16, patients either continued on OTEZLA or were switched from placebo to OTEZLA 30 mg twice daily through week 32. Patients initially randomized to OTEZLA who achieved a Psoriasis Area and Severity Index-75 response or PASI-50 response at week 32 were then re-randomized to either OTEZLA 30 mg twice daily or placebo. Celgene said improvements in the severity of preexisting nail, scalp and palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA responders through week 52 in ESTEEM 2; OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials; Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values.
13:01 EDTCELGCelgene announces positive Phase III study results evaluating Otezla
Celgene announced that results from its ongoing phase III LIBERATE trial evaluating Otezla, the company’s oral, selective inhibitor of phosphodiesterase 4, in patients with moderate to severe plaque psoriasis. The LIBERATE study evaluated the clinical efficacy and safety of either oral OTEZLA 30 mg twice daily or weekly subcutaneous etanercept 50 mg compared with placebo at week 16 in 250 patients who had no prior exposure to a biological therapy. It also examined the relative safety of a switch from etanercept to OTEZLA after week 16. At week 16, patients receiving OTEZLA 30 mg twice daily demonstrated statistically significant and clinically meaningful improvement when compared with placebo, as measured by the Psoriasis Area and Severity Index-75 response. At week 16, statistical significance was also achieved for patients receiving weekly injections of etanercept 50 mg when compared with placebo. A post-hoc analysis revealed no significant difference between OTEZLA and etanercept in PASI-75 at week 16. LIBERATE was not designed or powered to directly compare OTEZLA to etanercept.
10:51 EDTCELGStocks with call strike movement; DAL CELG
Delta Air Lines (DAL) September 57.5 call option implied volatility decreased 1% to 34, Celgene (CELG) July 145 call option implied volatility increased 3% to 28 according to IVolatility.
09:45 EDTCELGActive equity options trading on open
Subscribe for More Information
07:41 EDTCELGAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
06:26 EDTCELGCelgene price target raised to $144 from $135 at Piper Jaffray
Subscribe for More Information
06:10 EDTULTAUlta Salon implied volatility of 23 at lower end of index mean range
March 19, 2015
16:26 EDTSBUXOn The Fly: Closing Wrap
Stocks on Wall Street opened lower but turned mixed early in the day and remained that way for most of the session. The Dow and S&P spent most of the day deep in negative territory, while the Nasdaq managed to stay just above the flat line. Investors had a chance to digest yesterday’s comments from the Fed and may have re-considered whether it latest policy stance was as dovish as originally believed. ECONOMIC EVENTS: In the U.S., initial jobless claims rose 1K to 291K in the week ended March 14, which nearly matched the consensus 293K forecast. The current account deficit widened to $113.5B in Q4 from a revised deficit of $98.9B in Q3. The leading indicators for February rose 0.2% to 121.4, which was in-line with expectations. The Philadelphia Fed business outlook survey ticked down to a 5.0 one-year low from 5.2 in February, missing expectations for it to have risen a 7.0 reading. COMPANY NEWS: Apple (AAPL) joined the Dow Jones Industrial Average after the close last night, replacing AT&T (T). Shares of Apple finished their first day in the blue chip index down 97c, or 0.76%, at $127.50, while AT&T fell 39c, or 1.16%, to $33.20... Coffee giant Starbucks (SBUX) rose $1.92, or 2%, to close at $97.76 after hitting a new all-time high of $99.20 earlier. The move follows the company's investor day meeting yesterday, where it unveiled plans for two pilots of delivery services, reported a partnership to expand the distribution of its ready-to-drink products in China, and announced that its board has declared the sixth two-for-one split of the company’s stock since its IPO in 1992. Goldman Sachs and Wells Fargo were both unphased by the record highs and predicted the rally is not over for Starbucks in upbeat notes on the stock today. MAJOR MOVERS: Among the notable gainers was Amicus Therapeutics (FOLD), which rose $3.11, or 33.26%, to $12.46 after reporting positive results in meetings with the EMA and FDA. Also higher was Wynn Resorts (WYNN), which gained $7.19, or 5.85%, to $130.11 after research firm Brean Capital last night initiated coverage of the stock and several casino peers with Buy ratings. Among the noteworthy losers was Transocean (RIG), which fell $1.09, or 7.15%, to $14.16 after saying that it intends to scrap four rigs and noting that with those it has announced plans to scrap a total of 16 floaters. Also lower after its earnings report was diversified apparel company Vince Holding (VNCE), which fell $3.50, or 16.36%, to $17.89. INDEXES: The Dow fell 117.16, or 0.65%, to 17,959.03, the Nasdaq gained 9.55, or 0.19%, to 4,992.38, and the S&P 500 declined 10.23, or 0.49%, to 2,089.27.
13:59 EDTSBUXStarbucks volatility at low end of historic range as shares at fresh life high
Subscribe for More Information
13:27 EDTSBUXStarbucks hits fresh life high, levels to watch
Subscribe for More Information
13:00 EDTSBUXOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday, with Nasdaq slightly higher and the Dow and S&P 500 both down a bit more than 0.5%. The day’s economic reports were generally benign and are likely less significant to the trading action than participants having had some time to digest yesterday’s Fed comments. Immediately after the Fed's policy statement yesterday, the U.S. dollar fell as low as 1.10 against the euro, but that move was almost entirely reversed overnight. The dollar was back near pre-Fed levels against the euro early this morning, and similar moves were seen in pairs of the dollar and other major currencies. ECONOMIC EVENTS: In the U.S., initial jobless claims rose 1K to 291K in the week ended March 14, which nearly matched the consensus 293K forecast. The current account deficit widened to $113.5B in Q4 from a revised deficit of $98.9B in Q3. The leading indicators for February rose 0.2% to 121.4, which was in-line with expectations. The Philadelphia Fed business outlook survey ticked down to a 5.0 one-year low from 5.2 in February, missing expectations for it to have risen a 7.0 reading. In Europe, the Swiss National Bank left rates unchanged, cut its growth forecasts for the country's economy, said that it will intervene in currency markets as needed since it believes the Swiss Franc remains overvalued. COMPANY NEWS: Apple (AAPL) joined the Dow Jones Industrial Average today, replacing AT&T (T). Shares of the iPhone maker were down 0.5% near midday, while AT&T stock fell a bit more than 1%... Shares of coffee giant Starbucks (SBUX) hit a new all-time high of $98.50 earlier this afternoon following the company's investor day meeting yesterday. In conjunction with its meeting, Starbucks reaffirmed its goal to grow its market cap to $100B, unveiled plans for two pilots of delivery services, announced that its board has declared the sixth two-for-one split of the company’s stock since its IPO in 1992 and said it has entered into an agreement for Tingyi to manufacture and expand the distribution of Starbucks ready-to-drink products throughout mainland China. Goldman Sachs and Wells Fargo both issued upbeat notes on the stock today, saying that the coffee retailer's shares can continue to climb. MAJOR MOVERS: Among the notable gainers was Coronado Biosciences (CNDO), which gained 42% after announcing the formation of a new company, Mustang Therapeutics, focused on Chimeric Antigen Receptor, or CAR-T, technology. The company also announced a licensing agreement with NeuPharma for EGFR inhibitors. Also higher was Guess (GES), which gained 15% after reporting higher than expected profits for its fiscal fourth quarter. Among the noteworthy losers was Transocean (RIG), which fell 6% after having announced last night that four of its 5th generation UDW drillships will be cold stacked and the contract with ENI (E) for the Transocean Amirante was terminated. Transocean also said it intends to scrap four rigs, noting that with those it has announced plans to scrap a total of 16 floaters. Also lower following its earnings report was diversified apparel company Vince Holding (VNCE), which fell 16%. INDEXES: Near midday, the Dow was down 128.51, or 0.71%, to 17,947.68, the Nasdaq was up 3.15, or 0.06%, to 4,985.98, and the S&P 500 was down 13.36, or 0.64%, to 2,086.14.
10:45 EDTSBUXGoldman, Wells see room for Starbucks to rise further from record high
Shares of coffee giant Starbucks (SBUX) hit a new all-time high of $97.69 earlier this morning following the company's investor day meeting yesterday. Goldman Sachs and Wells Fargo both issued upbeat notes on the stock today, saying that the coffee retailer's shares can continue to climb. WHAT'S NEW: The growth of Starbucks' mobile offerings and lunch revenue, along with falling coffee prices, give it the opportunity to beat 2015 and 2016 consensus estimates, Goldman Sachs analyst Karen Holthouse wrote in a note to investors today. The analyst is increasingly confident that Starbucks can meet its guidance for a 5% increase in its comparative sales in both 2015 and 2016, driven by increases in prices, higher food sales, new coffee beverages, and its mobile system. Even after the recent run in the stock, its valuation "remains compelling," according to Holthouse, who raised her price target on the shares to $107 from $98 and kept a Buy rating on the name. After analyzing several recent presentations by Starbucks, Wells Fargo believes that the company has the right strategy to drive sustainable, ongoing growth. The company's many growth initiatives, including the expansion of its mobile payment systems, its tea and food offerings, its delivery initiative, and its packaged good business, should enable its growth to accelerate further, according to the firm. Following its sum-of-the-parts analysis, the firm thinks that investors are underappreciating Starbucks' value and failing to give the company credit for its tea and mobile business in particular. Given continued global volatility, investors will look for stable, consistent growth companies like Starbucks, Wells contended. It raised its price target range on Starbucks shares to $109-$111 from $94-$96 and kept an Outperform rating on the stock. WHAT'S NOTABLE: Yesterday, in conjunction with its meeting, Starbucks reaffirmed its goal to grow its market cap to $100B, unveiled plans for two pilots of delivery services, announced that its board has declared the sixth two-for-one split of the company’s stock since its IPO in 1992 and said it has entered into an agreement for Tingyi to manufacture and expand the distribution of Starbucks ready-to-drink products throughout mainland China. PRICE ACTION: In early trading, Starbucks climbed 1.7% to $97.44.
10:42 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
10:28 EDTGMCRKeurig Green Mountain 2.0 system traction disappointing, says Dougherty
Dougherty's said it is cautious on Keurig Green Mountain following checks indicating disappointing traction for the 2.0 brewer system.
09:37 EDTCELGActive equity options trading on open
Subscribe for More Information
08:14 EDTSBUXStarbucks shares can go higher, price target to $107 at Goldman
Goldman believes Starbucks shares can move higher despite their recent run and sees upside to 2015/16 consensus estimates driven by opportunities in mobile ordering, falling coffee prices, and positive lunch data-points. The firm believes mobile ordering is a significant growth driver and said investors appear dismissive of the opportunity. Goldman reiterates its Buy rating and raised its price target to $107 from $99 on Starbucks shares.
07:43 EDTSBUXStarbucks shares will continue to outperform, says Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use